Janssen Pharmaceutica Nv

Bing Innovations, LLC

Steven D Goldberg

Xiaohua Xue

Alec D Lebsack

Jing Liu

Wendy Eccles

Paul J Krawczuk

James Patrick Edwards

Steven P Meduna

Anne Fourie

David A Kummer

Curt A Dvorak

Wenying Chai

Craig R Woods

Hariharan Venkatesan

Daniel J Pippel

Christian Gege

John M Keith

Christoph Steeneck

Olaf Kinzel

Gerald Kleymann

William Moore Jones

Rachel T Nishimura

David R Schiff

Ronald L Wolin

Kelly J McClure

Aihua Wang

Maud J Urbanski

Michael D Hack

John J M Wiener

Mark S Tichenor

Natalie Anne Hawryluk

Mark D Rosen

Genesis M Bacani

Kevin Douglas Kreutter

Kristi A Leonard

John Depler Coleman

Jennifer Diane Venable

Brock T Shireman

Maxwell David Cummings

Virginia M Tanis

Connor L Martin

Zachary S Sales

Thomas Hoffmann

Charlotte Pooley Deckhut

Stefan McCarver

Elizabeth G Fennema

Alexander Valdes

Kyle T Tarantino

Steven Loskot

Alice Lee-Dutra

Anne E Fitzgerald

Umar Maharoof

Kent Barbay

Wai-Ping Leung

Timothy B Rhorer

Douglas Behenna

Michael Goldberg

Alexander Raymond Rovira

John Coleman

Deane Gordon

Luke E Hanna

Dongpei Wu

Joan M Pierce

Dougas C Behenna

Kristen Song

Virgnia M Tanis

Chris Evans

Aimee Rose De Leon-Tabaldo

Amy Strasner

Anne M Fourie

Joan Pierce

Alexander Rovira

Jonathan M Blevitt

Samuel E Deprimo

Kelly Mcclure

Kelly J Mcclure

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazine IL-17 inhibitor compounds

The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Imidazopyridazines as modulators of IL-17

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, Q, and Qare defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Phenyl and pyridinyl substituted imidazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Pyridinyl pyrazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, Q, R, R, R, R, A, and Aare defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl pyrazoles as modulators of RORgT

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl thiazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein:R, R, R, R, R, R, R, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-&#x3b3;-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Phenyl substituted pyrazoles as modulators of ROR&#x3b3;t

The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R-1-carbonyl)thiazole-2-carboxamide, wherein Ris defined in the specification.

Trifluoromethyl alcohols as modulators of ROR&#x3b3;t

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Thiazoles as modulators of ROR&#x3b3;t

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

FLAP modulators

The present invention comprises compounds of Formula I wherein:R, R, R, R, R, R, R, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

The present invention comprises compounds of Formula I. wherein:X, A, A, A, A, R, R, and Rare defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Growing community of inventors

Encinitas, CA, United States of America

Steven D Goldberg